• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Hemostemix Inc (OP: HMTXF )

    0.0350 +0.0050 (+16.67%)
    Streaming Delayed Price Updated: 2:01 PM EDT, May 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 350
    Open 0.0350
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0300
    Today's Range 0.0350 - 0.0350
    52wk Range 0.0300 - 0.1362
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
    Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
    Via Newsfile
    Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
    Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
    Via Newsfile

    Performance

    YTD
    -37.16%
    -37.16%
    1 Month
    -5.66%
    -5.66%
    3 Month
    -34.21%
    -34.21%
    6 Month
    -30.83%
    -30.83%
    1 Year
    -63.62%
    -63.62%

    More News

    Read More
    Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
    Via Newsfile
    Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
    Via Newsfile
    Topics Intellectual Property
    Exposures Intellectual Property
    Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
    Via Newsfile
    Hemostemix Announces Its Presentation to the Emerging Growth Conference
    Via Newsfile
    Topics Economy Intellectual Property
    Exposures COVID-19 Economy Intellectual Property
    Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
    Via Newsfile
    Hemostemix Announces Closing of $2,750,000
    Via IssueWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
    Via IssueWire
    Topics Intellectual Property Lawsuit
    Exposures Financial Intellectual Property Legal
    Your Fountain of Youth Trademarked by Hemostemix Inc.
    Via IssueWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Hemostemix Announces Closing of UNIT Private Placement
    Via IssueWire
    Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
    Via Benzinga
    Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
    Via Newsfile
    Topics Economy Intellectual Property
    Exposures COVID-19 Economy Intellectual Property
    Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
    Via Newsfile
    Topics Economy Intellectual Property
    Exposures COVID-19 Economy Intellectual Property
    Peter Lacey Increases His Investment in Hemostemix Inc.
    Via Newsfile
    Topics Intellectual Property
    Exposures Intellectual Property
    Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
    Via Newsfile
    Topics Economy Intellectual Property
    Exposures COVID-19 Economy Intellectual Property
    Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
    Via Newsfile
    Topics Economy Intellectual Property
    Exposures COVID-19 Economy Intellectual Property
    Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
    Via Newsfile
    Topics Economy Intellectual Property
    Exposures COVID-19 Economy Intellectual Property
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.